Circulars

Back to Circulars

18 June 2017

[Reminder] Enhancing Surveillance Of Dengue Fever All Public And Private Health Facilities

Reference: CIR-2017-SHN0745

To : All Healthcare Facilities - /Private sector /Dubai

The Preventive Services Center at Dubai Health Authority is  grateful for the continuous and joint cooperation of all the health care centers in Dubai for the shared goal of prevention, and control  communicable disease. In reference to the above subject

Referring to the above subject, dengue fever is the most common viral disease transmitted by mosquitoes. The global incidence of Dengue fever has grown dramatically in recent years, especially in the tropics and sub-tropical endemic regions, In addition there has been an observed increase in other viruses transmitted by Egyptian zebra mosquitoes such as the Zikavirus, yellow fever virus and Chikungunya virus.

Dengue represents a major health burden in countries with established endemic transmission and has become a leading cause of hospitalization and death in those countries. Globally the number of cases reported increased from 2.2 million in 2010 to 3.2 million in 2015.

There is no specific treatment for Dengue fever only supportive treatment, but early detection and access to proper medical care lowers fatality rates below 1%.

 

Importation of Dengue fever cases is possible to UAE through visitors to the country and travel to endemic areas. As Dengue fever,presenting symptoms can mimic common febrile illnesses . All practicing physicians are advised to consider the Dengue fever as differential diagnosis for Acute Febrile illnesses.

 

Dengue Fever is Notifiable according to Communicable diseases law 14 for the year 2014. Immediate notification is mandatory to the preventive service center in DHA .

 

Case Definition for reporting

 

Clinical description: In a patient with recent travel (2 weeks) to Dengue endemic area,an acute febrile illness (2-10 days) defined by the presence high fever(40°C/104°F), and two or more of the following:

 

  • retro-orbital or ocular pain
  • headache
  • rash
  • myalgia
  • arthralgia
  • leukopenia

    • Thrombocytopenia

    • hemorrhagic manifestations (e.g., positive tourniquet test, petechiae; purpura/ecchymosis; epistaxis; gum Dengue warning signs; Abdominal pain or tenderness; Persistent vomiting; clinicalfluid accumulation (e.g. ascites, pleural effusion); mucosal bleeding; lethargy/ restlessness; liver enlargement > 2 cm.

       

      Recommended Actions

      • Cases fulfilling clinical case definition should be investigated according to the above pathway

       

      Immediately notify the respective health department after collecting the sample as suspected Denguefever. The status to be confirmed on receipt of the laboratory test   bleeding; blood in vomitus, urine, or stool; or vaginal bleeding)
    • Contact for more details or information: 

    • Email: Islam Abdelrahman Omar Abdella IAAbdella@dha.gov.ae 

      Telephone: 0562253800 

      for full access on the circular, please refer to the following link:

       https://www.dha.gov.ae/Documents/external%20circular%20template%20%20%D8%AD%D9%85%D9%89%20%D8%A7%D9%84%D8%B6%D9%86%D9%83%20(002).pdf

       

       

       

       

       

Supporting Documents:

external circular template حمى الضنك (002).pdf:

View Document

Close